Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.
…
continue reading
Physicians' Education Resource® (PER®) is committed to advancing patient care through professional education. This podcast is a natural extension of PER®'s efforts to provide medical education for health care providers to stay up to date with advances in medical care, from diagnosis through treatment, with the ultimate goal of improving patient outcomes. Visit http://www.gotoper.com for more information.
…
continue reading
Are classic games deserving of their praise? Or have the unwashed masses been blinded by nostalgia? On the Retro Spectives Podcast, we tell you why you're wrong about the games you love.
…
continue reading
1
What 3 Big Trials Mean for Breast Cancer Practice
12:48
12:48
Spill senere
Spill senere
Lister
Lik
Likt
12:48
Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from three key studies. Erin Frances Cobain, MD, associate professor at the University of Michigan Rogel Cancer Center in Ann Arbor, explains how findings from the KEYNOTE-756, monarchE, and NATALEE clinica…
…
continue reading
1
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer
14:02
14:02
Spill senere
Spill senere
Lister
Lik
Likt
14:02
Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinica…
…
continue reading
1
"Where Do We Go From Here?" Targeted Therapies Lead to Challenging Choices in Breast Cancer
11:00
11:00
Spill senere
Spill senere
Lister
Lik
Likt
11:00
Newly approved targeted therapies for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are changing care. “We have an abundance of opportunities, but challenges with having to choose the right opportunity at the right time,” says Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the …
…
continue reading
1
S2 Ep16: Patient, Provider, & Caregiver Connection: Individualizing Care in Hemophilia A to Optimize Joint Health and Prevent Synovitis
40:44
40:44
Spill senere
Spill senere
Lister
Lik
Likt
40:44
Av PER® Spectives
…
continue reading
But can it run Crysis? This was the motto that surrounded every single PC build for literal years after the release of the game in 2007. Crytek were not satisfied with what they had achieved with Far Cry in 2004, and decided to push graphical hardware to its absolute limits with their brand new and shiny game. And boy, did they succeed, with a poor…
…
continue reading
1
After Practice Change in Unresectable Stage III NSCLC, Questions Remain
10:30
10:30
Spill senere
Spill senere
Lister
Lik
Likt
10:30
Data on the use of durvalumab after chemoradiotherapy transformed the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). “This is a real practice-changing observation from the PACIFIC trial,” said Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Cent…
…
continue reading
1
What "Incredibly Dramatic" Data on Osimertinib in NSCLC Mean for Practice
9:47
9:47
Spill senere
Spill senere
Lister
Lik
Likt
9:47
Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib significantly improves progression-free survival in patients with unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC) after chemoradiotherapy. “The benefits of osimertinib in this patient…
…
continue reading
1
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates
10:08
10:08
Spill senere
Spill senere
Lister
Lik
Likt
10:08
“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with …
…
continue reading
1
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says
11:27
11:27
Spill senere
Spill senere
Lister
Lik
Likt
11:27
Various survivorship guidelines for pediatric patients have been established, but “such guidelines do not exist in the adult world,” says Smita Bhatia, MD, MPH, director of the Institute for Cancer Outcomes and Survivorship and the Gay and Bew White Endowed Professor in Pediatric Oncology at the University of Alabama at Birmingham. With the number …
…
continue reading
1
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue”
12:00
12:00
Spill senere
Spill senere
Lister
Lik
Likt
12:00
Obstacles to “achieving a good, peaceful death” prevent many patients with cancer from the “dignified end” that they deserve, says Sunita Puri, MD, a palliative care physician and author. She and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss frustrations and …
…
continue reading
After their magnum opus that was Resident Evil 1, Capcom were not going to sit on their heels. Coming out just two years after the first in 1998, Resident Evil 2 sought to have everything the original had and much, much more. It connected its two character’s stories in far more meaningful ways, increased the size of each player's inventory (and the…
…
continue reading
1
FDA Approvals in Relapsed/Refractory CLL Set up "Difficult Choice"
9:59
9:59
Spill senere
Spill senere
Lister
Lik
Likt
9:59
When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have had some exciting new events," says Daniel A. Ermann, MD, a hematologist-oncologist and assistant professor at the University of Utah Huntsman Cancer Institute in Salt Lake City. The U.S. Food and Drug…
…
continue reading
1
Oncologists Struggling With Cancer Deaths Among Millennial Patients
11:36
11:36
Spill senere
Spill senere
Lister
Lik
Likt
11:36
Oncologists are struggling with the rising cancer mortality rate among millennial patients. "I think treating people our own age is definitely a trigger for a lot of people," said Sunita Puri, MD, a palliative-care physician and author. She spoke with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai…
…
continue reading
1
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree
12:23
12:23
Spill senere
Spill senere
Lister
Lik
Likt
12:23
Thoracic oncology was a major focus of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, says Sandip P. Patel, MD, a medical oncologist and professor of medicine at the University of California San Diego. Practice-changing data were presented in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), Dr. Patel…
…
continue reading
The Legend of Zelda is perhaps the most iconic video game series of all time. Boasting 19 mainline entries, and an endless swathe of critical acclaim and awards, it's hard to find someone who hasn’t at least heard of the action/adventure story of Link and Zelda. It all began back in 1986 with the release of the first game for the Famicom in Japan. …
…
continue reading
1
What Were the Biggest Data at ASCO 2024 in Kidney Cancer?
11:41
11:41
Spill senere
Spill senere
Lister
Lik
Likt
11:41
The biggest data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in kidney cancer focused on biomarkers, says Brian I. Rini, MD, chief of clinical trials and the Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center in Nashville. He discussed data from KEYNOTE-426 and several other key trials with Robert…
…
continue reading
1
What New “Elephant in the Room” Means for Bladder Cancer Care
14:00
14:00
Spill senere
Spill senere
Lister
Lik
Likt
14:00
Enfortumab vedotin plus pembrolizumab (EV/pembro) has “become the elephant in the room” when it comes to bladder cancer care, says Jonathan E. Rosenberg, MD, chief of genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. At the 2024 American Society of Clinical Oncology Annual Meeting, he discussed recent key ad…
…
continue reading
1
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice
12:08
12:08
Spill senere
Spill senere
Lister
Lik
Likt
12:08
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice Our host, Robert A. Figlin, MD, FACP, welcomes Melissa L. Johnson, MD, as a guest
…
continue reading
1
"We're Past the Inflection Point," as "Massive Change" Hits Breast Cancer Care
13:54
13:54
Spill senere
Spill senere
Lister
Lik
Likt
13:54
From ASCO 2024. When it comes to the use of antibody-drug conjugates (ADCs) in breast cancer care, "we're past the inflection point," says Hope S. Rugo, MD, a breast cancer oncologist and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.…
…
continue reading
1
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA"?
13:06
13:06
Spill senere
Spill senere
Lister
Lik
Likt
13:06
From ASCO 2024 The time it takes for a novel cancer therapy to go from investigational new drug application to U.S. Food and Drug Administration (FDA) approval is typically longer than a decade. “There has to be a better way,” says Bob T. Li, MD, PhD, MPH, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City and associate…
…
continue reading
Killer7 is one weird game. Developed in tandem by Grasshopper Manufacture and Capcom and first released in 2005, its very existence as a game defies description. Within moments of starting, you’re placed into a world with talking bondage ghosts, a TV channel that drains your blood, and abstract puzzles that would fit right into Resident Evil. Combi…
…
continue reading
1
"Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
12:32
12:32
Spill senere
Spill senere
Lister
Lik
Likt
12:32
From ASCO 2024, Dr. Robert Figlin speaks with Dr. Samer Al Hadadi from University of Arkansas. "Very Important" Myeloma Data: ASCO Highlights, Smoldering Challenges, and More.
…
continue reading
1
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"
10:29
10:29
Spill senere
Spill senere
Lister
Lik
Likt
10:29
From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center. Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"
…
continue reading
1
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says
25:13
25:13
Spill senere
Spill senere
Lister
Lik
Likt
25:13
From ASCO 2024 New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers "Fantastic" Potential, Expert Says. Dr. Robert Figlin speaks with Dr. Christian Blank from Leiden University
…
continue reading
1
Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"
10:46
10:46
Spill senere
Spill senere
Lister
Lik
Likt
10:46
From ASCO 2024, Dr. Robert Figlin welcomes Dr. Aditya Bardia from UCLA Health Jonsson Comprehensive Cancer Center. Should All Breast Cancer Patients Get T-DXd? "Results of DESTINY-Breast06 Do Suggest That"
…
continue reading
System Shock 2 is considered by many to be the finest immersive sim ever made. Released in 1999 in a coventure by Looking Glass Studios and Irrational Games, it sought to combine the classic 3D dungeon crawling of the original with pen and paper inspired RPG systems. While resource management and exploration were still a key part of the experience,…
…
continue reading
1
Oncologist Shortage “Has Gotten to the Crisis Level”
10:02
10:02
Spill senere
Spill senere
Lister
Lik
Likt
10:02
Especially in rural areas, the growing oncologist shortage has “gotten to crisis level,” says Harsha Vyas, MD, president and founding partner of Cancer Center of Middle Georgia in Dublin. “We just don’t have enough supply of medical oncologists/hematologists,” he tells Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology a…
…
continue reading
Over the years, we’ve played games from pretty much every genre under the sun, but there is one that is notably missing - the racing sim. We’ve dabbled with arcade racers like Burnout 3, and have played several kart racers - Diddy Kong and F-Zero GX to name a couple. But this is the first time we’re trying to learn how to actually drive a racing ca…
…
continue reading
1
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
9:20
9:20
Spill senere
Spill senere
Lister
Lik
Likt
9:20
The development of noncovalent Bruton tyrosine kinase (BTK) inhibitors and other advances in chronic lymphocytic leukemia treatment signify that the “future is really exciting,” says Jennifer A. Woyach, MD, professor in the Division of Hematology at The Ohio State University in Columbus. Dr. Woyach speaks with Robert A. Figlin, MD, the Steven Spiel…
…
continue reading
Hitman: Blood Money, first released in 2006 by Eidos, is considered by many to be the best Hitman game ever made. After the first few games played around with novel ideas and concepts to mixed success, Blood Money honed in on the formulae of specific, small and dense environments filled with ‘accidental’ scripted opportunities to murder your target…
…
continue reading
1
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
11:01
11:01
Spill senere
Spill senere
Lister
Lik
Likt
11:01
Given recent data, how should oncologists choose a tyrosine kinase inhibitor (TKI) in patients with EGFR-mutated non-small cell lung cancer (NSCLC), and when should chemotherapy be introduced? “It’s better to have choices than not,” explains Paul Bunn, MD, the Dudley Chair in Cancer Research at the University of Colorado in Aurora. Dr. Bunn discuss…
…
continue reading
1
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
11:16
11:16
Spill senere
Spill senere
Lister
Lik
Likt
11:16
The treatment of biochemical recurrence in prostate cancer “is set for rapid development over the next few years,” says Edwin M. Posadas, MD, medical director of the Center for Uro-Oncology Research Excellence at the Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center. Data from the recent EMBARK trial have changed practice for…
…
continue reading
1
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
11:26
11:26
Spill senere
Spill senere
Lister
Lik
Likt
11:26
The U.S. Food and Drug Administration’s recent accelerated approval of a tumor-infiltrating lymphocyte therapy in metastatic melanoma “is a real milestone,” after the approach was “pending for decades,” explains Jeffrey S. Weber, MD, PhD, deputy director at the NYU Langone Perlmutter Cancer Center. Dr. Weber, who was part of the team to first work …
…
continue reading
Final Fantasy VII is a landmark title not only for the JRPG genre, but for all video games. First released in 1997 and developed by Square, it took the format of the previous games and brought them to life with 3D models and environments. Featuring an ambitious and creative setting, a complicated plot with intrigue and a seemingly deep and engaging…
…
continue reading
1
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
10:48
10:48
Spill senere
Spill senere
Lister
Lik
Likt
10:48
Recent advances in metastatic urothelial carcinoma have meant that optimistic outcomes are “not as much of a fairytale,” says Robert Dreicer, MD, deputy director of the UVA Cancer Center and professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. From the recent approval of enfortumab vedotin plus pemb…
…
continue reading
1
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
11:57
11:57
Spill senere
Spill senere
Lister
Lik
Likt
11:57
Recent approvals by the U.S. Food and Drug Administration (FDA) and findings from pivotal clinical trials have changed care for patients with breast cancer that has progressed after frontline hormone therapy. Ruth M. O’Regan, MD, chair of medicine and Charles H. Dewey Professor at the University of Rochester in New York, highlights which recent dev…
…
continue reading
1
Controversies, Difficult Questions Arise in NSCLC Amid New Data
11:22
11:22
Spill senere
Spill senere
Lister
Lik
Likt
11:22
Recent data on the use of immunotherapy and targeted treatments in patients with advanced non-small cell lung cancer (NSCLC) have introduced a myriad of questions. These include controversial topics and difficult decisions, like when to incorporate CTLA-4 inhibition and what patients can expect from immuno-oncology monotherapy in the metastatic set…
…
continue reading
1
What FDA Approval of Belzutifan Means for Kidney Cancer Care
10:08
10:08
Spill senere
Spill senere
Lister
Lik
Likt
10:08
Belzutifan was recently approved by the U.S. Food and Drug Administration (FDA) for use in previously treated adults with advanced renal cell carcinoma. How should this drug best be incorporated into practice? Eric Jonasch, MD, professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Hous…
…
continue reading
1
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
12:04
12:04
Spill senere
Spill senere
Lister
Lik
Likt
12:04
CDK4/6 inhibitors “have really been a game changer” in metastatic breast cancer, according to Komal Jhaveri, MD, clinical director for early drug development and section head for endocrine therapy research at Memorial Sloan Kettering in New York City. However, optimal treatment strategies have been complicated by a lack of head-to-head trials. Dr. …
…
continue reading
1
S2 Ep15: PER®Spectives: Advancing Treatment in nAMD and DME with Novel Therapies
18:11
18:11
Spill senere
Spill senere
Lister
Lik
Likt
18:11
This PER®Spectives™ podcast examines opportunities for extended treatment intervals associated with newer therapies for patients with neovascular age-related macular degeneration or diabetic macular edema. In this podcast, experts Arshad Khanani, MD, Ferhina Ali, MD, and Michael Singer, MD, offer real-world data and personal insights into the use o…
…
continue reading
Rain World is a game that was released to very mixed reviews. With a whopping 59 on Metacritic, it was panned for its controls, difficulty, tedium and general obtuseness. But take a gander at the community reviews and you get a very different picture. The thing is, Rain World can at times be all the things that its critics hate so much that they gi…
…
continue reading